Fig. 6

Selected molecules secreted from calcitriol-treated CAFs derived from tumors of patients with different clinical characteristics. A1–F1 data presented for CAFs from all patients. A2–F2 data presented for CAFs derived from tumors of patients with different clinical characteristics. CAFs were treated with calcitriol (cal; 1 nM or 10 nM) for 72 h. A–C–C motif chemokine ligand 2 (CCL2), B-C-X-C motif chemokine ligand 12 (CXCL12), C tenascin C (TNC), D metalloproteinase 9 (MMP9), E hepatocyte growth factor (HGF), F osteopontin (OPN). Patients were classified into groups according to plasma 25(OH)D₃ levels (VD₃, < 30 ng/mL—deficient (n = 34), > 30 ng/mL—normal (n = 17)), plasma FSH levels (< 25.8 mIU/mL—premenopausal (n = 18), > 25.8 mIU/mL—postmenopausal (n = 33)) and regional or distant metastasis presence (if any—metastatic (n = 16), otherwise nonmetastatic (n = 35)). The concentration of secreted protein was calculated based on a standard curve using CurveExpert 1.4. The results were normalized to the untreated control. Data are presented as the mean ± SEM. Statistical analysis was carried out using Student’s t-test or the Mann‒Whitney U test for single comparisons and one-way ANOVA or the Kruskal‒Wallis test for multiple comparisons. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001